Loading content…
Drug family · 2 brands
Exenatide family — Byetta, Bydureon BCise
GLP-1 receptor agonist (synthetic exendin-4). FDA-approved since 2005. Trial weight loss range: ~4.5-5% across pivotal trials.
Quick answer
exenatide is a GLP-1 receptor agonist (synthetic exendin-4). FDA-approved brand-name medications containing exenatide: Byetta, Bydureon BCise. Trial weight loss varies from ~4.5-5% across pivotal trials. Each brand is FDA-approved for a specific indication; prescribers choose based on patient diagnosis and insurance coverage.
- Manufacturer: AstraZeneca
- FDA indications: Type 2 diabetes
- Trial weight loss: ~4.5-5%
- Lowest weight loss efficacy in GLP-1 class
- Frequency: Twice-daily (Byetta) or weekly (Bydureon BCise)
- Historical context: First GLP-1 agonist approved by FDA (2005)
Mechanism of action
Exenatide is synthetic exendin-4, originally isolated from the Gila monster lizard saliva. 53% sequence homology with human GLP-1 but resistant to DPP-4 degradation. First-generation GLP-1 agonist FDA-approved in 2005 (Byetta, twice-daily) followed by extended-release formulation (Bydureon BCise, weekly). Established efficacy for type 2 diabetes glycemic control with modest weight loss benefit.
FDA-approved brands containing exenatide
All brands share active ingredient exenatide but differ in indication, dosing, and formulation.
Alternatives outside the exenatide family
If exenatide options don't fit, these GLP-1 medications use a different active ingredient:
Common questions
Is exenatide still relevant in 2026?
Exenatide products are generally considered second-line GLP-1 options in 2026, with most new prescriptions going to semaglutide, tirzepatide, or dulaglutide. However, patients stable on Byetta or Bydureon BCise often continue therapy. Cost may be a factor as generic exenatide approvals approach.
Why was Byetta twice-daily in this weekly?
Byetta has a short 2.4-hour half-life requiring twice-daily dosing for therapeutic levels. Bydureon BCise uses microsphere encapsulation technology to slowly release exenatide over 7 days, enabling weekly dosing. Newer molecules (semaglutide, dulaglutide) achieve weekly dosing via modified molecular structure rather than delivery technology.
References
SUSTAIN-6 trial: Semaglutide and Cardiovascular Outcomes (Marso et al., NEJM)(2016)
SURPASS-2 trial: Tirzepatide vs Semaglutide in Type 2 Diabetes (Frias et al., NEJM)(2021)
LEADER trial: Liraglutide and Cardiovascular Outcomes in T2D (Marso et al., NEJM)(2016)
Glucagon-Like Peptide-1 Receptor Agonists: Mechanisms and Clinical Use (Drucker, Cell Metabolism)(2018)
Tirzepatide GIP/GLP-1 Dual Agonism: Mechanism Review (Lancet Diabetes & Endocrinology)(2021)
GLP-1 Effects on Gastric Emptying: Pharmacology Review (American J Physiology)(2020)